Pharmaceuticals

[New] Spending on prescription drugs in the US is on the rise and is projected to far outpace growth in other parts of the health care sector in 2020.
The high prevalence of cardiovascular disease, coupled with the increasing emphasis on the research and development of new drugs will open up a huge potential for the companies operating in the market in this market.
With more than 1,400 new biological drugs currently in development, a number that is increasing year-on-year, the market is expected to grow to an unprecedented $285 billion by 2023 (up from just $84 billion in 2017).
The global market for natural & plant-derived drugs market is expected to reach $35.4 billion in 2020, with a Compound Annual Growth Rate of 6.6% from 2015 to 2020.
Amid competitive threats from several new MS drugs - and a patent dispute in which a key decision is expected next week-Biogen managed to grow sales of Tecfidera 5% during the fourth quarter to $1.2 billion.
The Acceleron drug could perform in the top quartile of PAH drugs, putting its annual revenue potential in the $1.5 billion to $2 billion range within five years of reaching the market.
With the Trump administration likely to continue to remove some of the barriers in the FDA approval process over the coming years, it's likely that more and more of SBIO's picks will be successful in bringing new drugs to market.
Always a cost-competitive market, the generics market, particularly the US market, has seen recent restructuring due to product and cost pressures and a key issue going forward for 2020 is how the market will shape out in 2020.
The global cardiovascular drugs market is anticipated to reach the value of approximately US$ 91.0 Bn by 2025.
Blockbuster specialty drugs and new technologies will fuel revenue growth and expand the profit pool by 35% to $170 billion by 2024.
BioMarin Pharmaceuticals' hemophilia A gene therapy valoctocogene roxaparvovec could be on the market in mid-2020, making the question of how to structure reimbursement an immediate concern for payers.
Drug allergy treatment and drug market size are expected to achieve high growth over the forecast period from 2019 to 2025.
Passage of legislation to curb ridiculously high medication prices and price increases will not only make medicines more accessible to patients but will reduce government expenditures on drugs by more than $345 billion dollars over 10 years, according to the US Congressional Budget Office.
The global vanillin market is expected to expand at healthy CAGR of around 7-10% during the forecast period (2016-2025), due to growth in end-use industries such as food & beverages and pharmaceuticals.
The Peptide and Anticoagulant Drugs Market is forecasted on the basis of revenue analysis, product standard and strategic developments of key Market players.
In Louisiana, the first state to announce a flat-rate hepatitis C drug agreement, Asegua, a subsidiary of Gilead, will provide an unlimited amount of its drug, Epclusa, for a set price - roughly $58 million a year for five years, or up to $290 million.
Novartis has agreed a $9.7bn (£7.6bn) cash deal to acquire The Medicines Company, betting that the US drug maker will come good on a new drug designed to control cholesterol levels.
The Food and Drug Administration is expected to rule by late spring next year on whether to approve a new drug for spinal muscular atrophy.
China recently announced that a new drug, meant to potentially treat Alzheimer's disease, will be available to Chinese patients by the end of this year.
The Global Diabetes Drugs Market is expected to reach US$ 78,261.7 mn by 2026 owing to rising prevalence of diabetes the world over.
Combined with the highly successful launch of Rinvoq, AbbVie could see sales of both drugs top $1 billion next year - significantly higher than consensus estimates of around $800 million.
The projected costs are expected to rise to billions of dollars with Alzheimer's disease and Dementia expected to become a global epidemic in the next 20 years.

See full forecast

Last updated: 18 February 2020